VivoSeq
Gastroenterology

Inflammatory Bowel Disease

115

Pipeline Programs↗

37

Active Trials↗

44

Companies Involved↗

Inflammatory Bowel Disease is a highly competitive landscape with 115 programs across 44 companies. The most active players are Tanabe Pharma Corporation, Nanjing Bioheng Biotech Co., Ltd., Mirador Therapeutics, Inc.. 33 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

47/100

Mech. Concentration

12/100

Completion Rate

83/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

1 program

Phase 1N

Nanjing Bioheng Biotech Co., Ltd.

1 program

Phase 1M

Mirador Therapeutics, Inc.

2 programs

Phase 2A

Arena Pharmaceuticals

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2Biogen logo

Biogen

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical31

Polyethylene Glycol

Bayer

Nabilone

Bausch Health Americas, Inc.

Pyridoxine

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Guselkumab

Johnson & Johnson

Dexamethasone

Aspen Global Incorporated

Phase 112

Abbvie-Gp2020

AbbVie

Methylprednisolone

Pfizer

Vedolizumab

Takeda

Apixaban

Bristol-Myers Squibb

Curcumin

Merck & Co.

Phase 226

Golimumab

Johnson & Johnson

Filgotinib

Gilead

Risankizumab

AbbVie

BMS-986142

Bristol-Myers Squibb

BMS-509744

Bristol-Myers Squibb

Phase 313

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Infliximab

Organon and Co

Mirikizumab

Eli Lilly

Dapagliflozin

AstraZeneca

Thalidomide

Bristol-Myers Squibb

Approved33

Amitriptyline

AstraZeneca

Fenofibrate

Jagotec

Tirzepatide

Eli Lilly

Ergocalciferol

Alnylam Pharmaceuticals

Deucravacitinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Analysis

Modality Breakdown

84%

Small molecule

105 of 125 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody119%Vaccine54%Cell therapy22%Protein / enzyme1<1%Peptide1<1%

Small molecule leads; the ring shows all 125 classified programs, each share of the total. Modality classified for 97% of 152 pipeline programs.

Analysis

Trial Status

148

clinical trials

Completed68 · 46%
Unknown status29 · 20%
Recruiting17 · 11%
Not yet recruiting16 · 11%
Terminated9 · 6%
Withdrawn5 · 3%
Other4 · 3%

Clinical Trials

Trial Activity

148 trials

A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2·NCT07229950·66 enrolled
Vitamin B6 Aids in Treating Inflammatory Bowel Disease
Recruiting·—·N/A·NCT06512441·220 enrolled
PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease
Recruiting·PPontificia Universidad Catolica de Chile·N/A·NCT06758024·72 enrolled
Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease
Recruiting·—·N/A·NCT06780683·174 enrolled
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Recruiting·MMirador Therapeutics, Inc.·Phase 2·NCT07113522·140 enrolled
Impact Of The Gut Microbiota On Host Cells Energy Metabolism in Health And In Inflammatory Bowel Disease
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07300553·45 enrolled
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
Recruiting·UUniversity of Miami·Phase 4·NCT06774079·24 enrolled
Research on the Mechanisms of Treatment Non-response in Inflammatory Bowel Disease Based on Multi-omics Technology
Recruiting·NNanfang Hospital, Southern Medical University·N/A·NCT06447870·30 enrolled
A Prospective Cohort Study Evaluating the Efficacy and Safety of Guselkumab (GUS) With JAK Inhibitors in Patients With Difficult-To-Treat Inflammatory Bowel Disease (IBD)
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07487311·80 enrolled
Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease
Recruiting·PPeking University First Hospital·N/A·NCT07181525·200 enrolled
Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease
Recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT06606808·18 enrolled
Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease
Recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT06117423·21 enrolled
Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease
Recruiting·—·Phase 2/3·NCT05986136·50 enrolled
Microbial Restoration in Inflammatory Bowel Diseases
Recruiting·SSt Vincent's Hospital Melbourne·Phase 1/2·NCT04970446·120 enrolled
A Natural History Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001184·1,000 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)